Aurobindo Pharma has announced that its Board of Directors will meet on November 5, 2025, to consider and approve the Standalone & Consolidated Unaudited Financial Results for the second quarter and half year ended September 30, 2025. The trading window, previously closed from July 1, 2025, will remain closed until November 7, 2025, and reopen on November 8, 2025.
Board Meeting Announcement
Aurobindo Pharma has scheduled a meeting of its Board of Directors to be held on November 5, 2025. During this meeting, the board will review and approve the unaudited financial results.
Financial Results Consideration
The primary agenda of the board meeting is to consider and approve the Standalone & Consolidated Unaudited Financial Results for the second quarter (Q2: Jul-Sep) and half year which ended on September 30, 2025.
Trading Window Closure
The company has previously announced the closure of its trading window, which commenced on July 1, 2025. This window will remain closed until November 7, 2025, and will subsequently reopen for trading on November 8, 2025. This measure is in place to ensure compliance with regulations during the finalization of financial results.
Source: BSE
